BNTX ▼ -1.2% - BioNTech SE
$BNTX - BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
13-OCT-2026 06:45 AM ET
Share this post
More filings for $BNTX
BNTX ▲ +0.4% - BioNTech SEOct 26, 2026BNTX ▼ -1.4% - BioNTech SEOct 25, 2026BNTX ▼ -0.7% - BioNTech SEOct 22, 2026BNTX ▲ +0.2% - BioNTech SEOct 19, 2026BNTX ▲ +3.4% - BioNTech SESep 14, 2026BNTX ▼ -7.2% - BioNTech SEAug 28, 2026
View full $BNTX filing history →💬 Comments
Loading comments…
Leave a comment